Download Files:
Abarelix
$180 – $1,140
Products Details
Product Description
– Abarelix (R3827; PPI 149) is a potent gonadotrophin-releasing hormone (GnRH) antagonist, used for prostate cancer treatment.
Web ID
– HY-13534
Storage Temperature
– -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)
Shipping
– Blue Ice
Applications
– Cancer-programmed cell death
Molecular Formula
– C72H95ClN14O14
References
– [1]Koechling W, et al. A novel GnRH antagonist, causes minimal histamine release compared with abarelix in an ex vivo model of human skin samples. Br J Clin Pharmacol. 2010 Oct;70(4):580-7.|[2]Kirby RS, et al. Abarelix and other gonadotrophin-releasing hormone antagonists in prostate cancer. BJU Int. 2009 Dec;104(11):1580-4.|[3]Debruyne F, et al. Abarelix for injectable suspension: first-in-class releasing hormone antagonist for prostate cancer. Future Oncol. 2006 Dec;2(6):677-96.
CAS Number
– 183552-38-7
Molecular Weight
– 1416.06
Compound Purity
– 99.62
SMILES
– C[C@H](C(N)=O)NC([C@H]1N(C([C@H](CCCCNC(C)C)NC([C@H](CC(C)C)NC([C@@H](CC(N)=O)NC([C@H](CC2=CC=C(C=C2)O)N(C([C@H](CO)NC([C@@H](CC3=CC=CN=C3)NC([C@@H](CC4=CC=C(Cl)C=C4)NC([C@@H](CC5=CC=C6C=CC=CC6=C5)NC(C)=O)=O)=O)=O)=O)C)=O)=O)=O)=O)CCC1)=O
Clinical Information
– Launched
Research Area
– Cancer; Endocrinology
Solubility
– DMSO : ≥ 14.2 mg/mL
Target
– GnRH Receptor
Pathway
– GPCR/G Protein
Product type
– Peptides
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
